Welcome to our dedicated page for Entero Therapeutics SEC filings (Ticker: ENTO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Entero Therapeutics, Inc. (NASDAQ: ENTO) SEC filings page on Stock Titan aggregates the company’s regulatory disclosures from the U.S. Securities and Exchange Commission, including Forms 10-K, 10-Q, 8-K, registration statements, and other required reports. These documents provide detailed information on Entero’s dual focus: late clinical-stage development of targeted, non-systemic therapies for gastrointestinal diseases and the integration of Grid AI, a grid-edge, AI-driven software and device platform.
In its S-1/A registration statement, Entero outlines its GI pipeline and describes Adrulipase as a recombinant lipase enzyme for exocrine pancreatic insufficiency associated with cystic fibrosis and chronic pancreatitis. The same filing explains that the company is a smaller reporting company with common stock listed on the Nasdaq Capital Market under the symbol ENTO. Investors can use annual reports on Form 10-K and quarterly reports on Form 10-Q, when filed, to review research and development activities, risk factors, and financial statements.
Recent Forms 8-K are particularly important for understanding Entero’s corporate transition. One 8-K details the share exchange agreement through which Entero acquired 100% of Grid AI Corp, issuing common and Series H non-voting convertible preferred stock and granting Grid AI shareholders the right, subject to conditions, to designate a majority of directors. Other 8-K filings describe Nasdaq correspondence regarding compliance with Listing Rule 5550(b)(1), a Securities Purchase Agreement for a promissory note and warrant financing, and governance arrangements related to Grid AI’s shareholders and board representation.
A Form 12b-25 (NT 10-Q) explains that Entero requested additional time to file a quarterly report due to the complexity of accounting for the Grid AI acquisition. Together, these filings allow investors to track equity structure, financing arrangements, listing compliance, and the accounting treatment of major transactions. On Stock Titan, AI-powered tools summarize lengthy documents such as 10-Ks, 10-Qs, and 8-Ks, highlight key terms in registration statements like the S-1/A, and help surface notable items in ownership and governance disclosures, so readers can more quickly interpret ENTO’s regulatory history and ongoing obligations.
Entero Therapeutics, Inc. reported a Q3 2025 net loss of $1,152,809, improving from $2,580,971 a year earlier as operating expenses declined. For the first nine months of 2025, net loss narrowed to $3,410,700 from $5,821,067 in the prior-year period. Cash and cash equivalents were $2,517,218 at September 30, 2025, with an accumulated deficit of $205,798,707, and management states there is substantial doubt about the company’s ability to continue as a going concern.
Total assets rose to $135,370,340 from $85,409,506, driven by the March 2024 ImmunogenX acquisition and the September 30, 2025 acquisition of Grid AI Corp., which added developed technology, customer relationships, trade name intangibles and $25,796,163 of goodwill. Assets and liabilities related to ImmunogenX, including Latiglutenase and CypCel, are classified as held for sale and treated as discontinued operations. The Grid AI deal also introduced a non-controlling interest of $5,287,000 and new Series H preferred stock that is convertible into common shares subject to shareholder approval.
Entero Therapeutics, Inc. filed a Form 12b-25 to notify that its Form 10-Q for the quarter ended September 30, 2025 will be filed late. The company is still reviewing the accounting treatment of its acquisition of GridAI Corp. and needs more time to ensure the financial statements comply with applicable accounting standards. Under Rule 12b-25, Entero expects to file the quarterly report no later than the fifth calendar day after the original due date.
Entero Therapeutics (ENTO) reported that on October 17, 2025, the stockholders of GridAI Corp waived their right to appoint two directors to Entero’s Board as provided in Section 5.09 of the Share Exchange Agreement dated September 30, 2025. The waiver remains in effect until Entero’s shareholders approve the appointment of such directors at a duly called meeting in accordance with applicable laws.
This update follows the previously disclosed agreement referenced in the company’s October 6, 2025 filing and reflects a governance step that defers board appointments pending shareholder approval.
Entero Therapeutics (ENTO) reported that Nasdaq has confirmed the company is back in compliance with the minimum stockholders’ equity requirement under Listing Rule 5550(b)(1). Compliance was affirmed in a letter dated October 28, 2025, following Entero’s October 6 disclosure tied to a September 30 share exchange with GridAI.
The company had previously fallen out of compliance after reporting stockholders’ equity of ($3,876,738) as of December 31, 2024, below the $2.5 million minimum. Nasdaq had granted an extension through October 8, 2025, to regain compliance. Nasdaq cautioned that if Entero does not evidence compliance in its next periodic report, the company may face delisting, with the option to appeal to a Hearings Panel.
Entero Therapeutics entered a Securities Purchase Agreement allowing a private placement of up to $5,000,000 in promissory notes and a common stock purchase warrant for up to 1,520,000 shares, with subsequent closings permitted.
At the initial closing on October 17, 2025, the company received $500,000 in gross proceeds by issuing a $500,000 non‑interest‑bearing, non‑convertible Note maturing one year and one day from issuance, which the company may extend in one‑year‑and‑one‑day increments. It also issued a Warrant to purchase up to 200,000 shares at an exercise price of $2.50 per share, exercisable upon stockholder approval and expiring five years after that approval.
The Warrant size may adjust pro rata with additional investments, up to 1,520,000 shares, includes a 4.9% Beneficial Ownership Limitation, and may be exercised cashlessly if the underlying shares are not registered. Entero plans to use proceeds for general corporate purposes, and will seek stockholder approval and file a registration statement for the resale of the Warrant shares.
Entero Therapeutics, Inc. filed a Form 8-K reporting several exhibits tied to a material corporate action. The company filed a Certificate of Designation establishing Series H Non-Voting Convertible Preferred Stock with the Delaware Secretary of State on October 1, 2025. The filing also lists a Form of Registration Rights Agreement, a Share Exchange Agreement, and a Press Release dated October 1, 2025 as exhibits. The cover page interactive XBRL is included. The Form 8-K is signed by Jason D. Sawyer as Interim Chief Executive Officer on October 6, 2025, indicating the company provided contemporaneous disclosure of these actions.
Document scope and corporate actions: This S-1/A incorporates the company’s 2024 Annual Report on Form 10-K and 10-Qs for March 31, 2025 and June 30, 2025 and states that all historical share and per-share figures reflect a 1-for-3 reverse stock split effective August 18, 2025. The filing lists authorized capital of 100,000,000 common shares and 10,000,000 preferred shares.
Intellectual property and patents: The filing references multiple patent families, including European and U.S. patents for a Yarrowia lipolytica lipase (European expiry June 15, 2026; U.S. expirations Sept 11, 2028 and July 17, 2026) and issued U.S. patents for inflammatory-condition treatments expiring Sept 1, 2036 and patents directed to niclosamide use expiring March 31, 2040.
Other material items: The prospectus lists risks and cost items related to development, regulatory approval, manufacturing, commercialization, patent prosecution and personnel. It discloses selling-stockholder warrant holdings with a 4.9% beneficial ownership exercise limitation and includes signatures dated September 10, 2025.
Document scope and corporate actions: This S-1/A incorporates the company’s 2024 Annual Report on Form 10-K and 10-Qs for March 31, 2025 and June 30, 2025 and states that all historical share and per-share figures reflect a 1-for-3 reverse stock split effective August 18, 2025. The filing lists authorized capital of 100,000,000 common shares and 10,000,000 preferred shares.
Intellectual property and patents: The filing references multiple patent families, including European and U.S. patents for a Yarrowia lipolytica lipase (European expiry June 15, 2026; U.S. expirations Sept 11, 2028 and July 17, 2026) and issued U.S. patents for inflammatory-condition treatments expiring Sept 1, 2036 and patents directed to niclosamide use expiring March 31, 2040.
Other material items: The prospectus lists risks and cost items related to development, regulatory approval, manufacturing, commercialization, patent prosecution and personnel. It discloses selling-stockholder warrant holdings with a 4.9% beneficial ownership exercise limitation and includes signatures dated September 10, 2025.
Document scope and corporate actions: This S-1/A incorporates the company’s 2024 Annual Report on Form 10-K and 10-Qs for March 31, 2025 and June 30, 2025 and states that all historical share and per-share figures reflect a 1-for-3 reverse stock split effective August 18, 2025. The filing lists authorized capital of 100,000,000 common shares and 10,000,000 preferred shares.
Intellectual property and patents: The filing references multiple patent families, including European and U.S. patents for a Yarrowia lipolytica lipase (European expiry June 15, 2026; U.S. expirations Sept 11, 2028 and July 17, 2026) and issued U.S. patents for inflammatory-condition treatments expiring Sept 1, 2036 and patents directed to niclosamide use expiring March 31, 2040.
Other material items: The prospectus lists risks and cost items related to development, regulatory approval, manufacturing, commercialization, patent prosecution and personnel. It discloses selling-stockholder warrant holdings with a 4.9% beneficial ownership exercise limitation and includes signatures dated September 10, 2025.